Bio-Rad Launches Annexin V StarBright Conjugates for Apoptosis Detection via Flow Cytometry

Annexin V StarBright™ Conjugates Offer Increased Choice and Flexibility for Apoptosis Detection in Conventional and Full Spectrum Flow Cytometry

7 August 2024 -- California, US -- Bio-Rad Laboratories, Inc, a global leader in life science research and clinical diagnostics products, today announced the launch of annexin V conjugated to eight StarBright Dyes: SBUV400, SBUV795, SBV440, SBV515, SBV790, SBB675, SBB765, SBY800. The new Annexin V StarBright conjugates support detection of early apoptotic cells by flow cytometry, offering an increased range of fluorophore options.

Bio-Rad’s range of annexin V conjugates provides researchers with a variety of choices, especially important when including apoptosis detection in multicolor immunophenotyping panels in both conventional and full spectrum flow cytometry. Annexin V StarBright conjugates enable full utilization of all the common laser lines found in flow cytometers such that common viability dye and fluorescent protein emission wavelengths can be avoided. This, combined with the narrow excitation and emission of StarBright Dyes, reduces spillover and spreading to provide high-resolution data.

“Introduction of Annexin V StarBright Dye conjugates offers customers greater choice and flexibility when detecting apoptosis in both conventional and full spectrum flow cytometry,” said Hilary Mavor, Marketing Director, Life Science Group at Bio-Rad Laboratories. “Bio-Rad has one of the most comprehensive ranges of annexin V conjugates, allowing users to follow best practice and accurately detect apoptosis with minimum spillover with their viability dyes.”

Visit bio-rad.com/annexin-v-kit to learn more about Bio-Rad annexin V conjugates.
BIO-RAD, STARBRIGHT are trademarks of Bio-Rad Laboratories, Inc. In certain jurisdictions.

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 8,000 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, food safety and environmental quality laboratories, and biopharmaceutical companies. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com.